• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Scientific Publications by FDA Staff

  • Print
  • Share
  • E-mail

Search Publications



Starting Date

Ending Date

Order by

Entry Details

Trends Biotechnol 2015 Jan;33(1):27-34

Fc fusion as a platform technology: potential for modulating immunogenicity.

Levin D, Golding B, Strome SE, Sauna ZE


The platform technology of fragment crystallizable (Fc) fusion, in which the Fc region of an antibody is genetically linked to an active protein drug, is among the most successful of a new generation of bioengineering strategies. Immunogenicity is a critical safety concern in the development of any protein therapeutic. While the therapeutic goal of generating Fc-fusion proteins has been to extend half-life, there is a critical mass of literature from immunology indicating that appropriate design of the Fc component has the potential to engage the immune system for product-specific outcomes. In the context of Fc-fusion therapeutics, a review of progress in understanding Fc biology suggests the prospect of engineering products that have an extended half-life and are able to modulate the immune system.

Category: Journal Article, Review
PubMed ID: #25488117 DOI: 10.1016/j.tibtech.2014.11.001
Includes FDA Authors from Scientific Area(s): Biologics
Entry Created: 2014-09-23 Entry Last Modified: 2014-12-28